Group 1 - Block & Leviton is investigating PetMed Express, Inc. for potential securities law violations following significant delays in financial reporting and executive resignations [1][2][4] - PetMed Express announced a delay in its 2025 fourth quarter and year-end financial results on June 10, 2025, and further delayed the filing due to an internal investigation into revenue recognition [2] - The company's stock price has fallen by almost 30% after the resignation of its CEO and CFO on August 12, 2025 [2] Group 2 - Investors who have lost money in PetMed Express may be eligible to recover losses and are encouraged to contact Block & Leviton for more information [3][5] - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors [7] - Whistleblowers with non-public information about PetMed Express may assist in the investigation and could receive rewards of up to 30% of any successful recovery [6]

DELRAY BEACH, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced that its Chief Executive Officer, Sandra Campos, and Chief Financial Officer, Robyn D’Elia, have resigned from their positions and employment with the Company. As part of the leadership changes, Leslie C.G. Campbell, the Chair of the Company’s Board of Directors (the “Board”), has assumed the role of Interim Chief Executive Officer, and Douglas ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PetMed and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potentia ...

Company Overview - PetMed Express, Inc. is an online pet pharmacy that provides prescription and non-prescription medications, supplements, and pet supplies directly to consumers across the United States [3]. Allegations and Stock Impact - On June 10, 2025, PetMed announced a delay in releasing its fourth-quarter and full-year 2025 earnings due to the need for additional time to complete its year-end audit process, resulting in a stock price decline of $0.47, or 11.2%, closing at $3.72 per share on June 11, 2025 [3]. - On July 1, 2025, PetMed disclosed another delay in filing its annual report with the SEC, linked to an internal investigation by the Audit Committee regarding whistleblower complaints about revenue recognition, promotional coupon impacts, and company culture. This announcement led to a further stock price drop of $0.05, or 1.51%, closing at $3.27 per share on the same day [3]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving PetMed, stemming from allegations of providing misleading business information to investors [1].

Core Viewpoint - PetMed Express, Inc. has received a notice from Nasdaq regarding non-compliance with listing rules due to the late filing of its Annual Report on Form 10-K for the fiscal year ending March 31, 2025 [1][3]. Group 1: Compliance and Filing Status - The notice indicates that the company must submit a plan to regain compliance within 60 days, by September 1, 2025, and may receive an extension of up to 180 days to regain compliance [3]. - The company filed a Notification of Late Filing on Form 12b-25, stating it was unable to file the Form 10-K on time due to ongoing efforts to compile and analyze necessary financial information [3][4]. - The company is working diligently to complete its financial statements and plans to file the Form 10-K as soon as possible to regain compliance with Nasdaq listing rules [4]. Group 2: Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, operating as a national online pharmacy licensed across all 50 states [5]. - The company offers a comprehensive range of pet health solutions, including pharmaceuticals, compounded medications, and OTC supplements, focusing on value, convenience, and care for pet wellness [5].

Core Viewpoint - Block & Leviton is investigating PetMed Express, Inc. for potential securities law violations following a delayed 10-K filing and internal investigations into revenue recognition [2][4]. Group 1: Investigation Details - The investigation is prompted by concerns related to a Q4 promotional campaign and internal accounting controls [2]. - Block & Leviton may file an action to recover losses on behalf of investors who have lost money in PetMed Express [4]. Group 2: Eligibility and Contact Information - Any investor who purchased PetMed Express common stock and experienced a decline in share value may be eligible to participate in the investigation [3]. - Investors are encouraged to contact Block & Leviton for more information via their case website, email, or phone [5]. Group 3: Whistleblower Information - Individuals with non-public information about PetMed Express are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - PetMed Express, Inc. is currently unable to file its Form 10-K for the fiscal year ended March 31, 2025, due to ongoing investigations related to revenue recognition and customer complaints, but does not expect a material impact on its preliminary financial results [2]. Company Update - The Company filed a Form 12b-25 on June 16, 2025, indicating it would not meet the deadline for the 2025 Form 10-K filing [2]. - The Audit Committee is investigating anonymous reports regarding revenue recognition timing for autoship orders, a $50 coupon promotion, and the Company's culture and control environment [2]. - External legal counsel has been engaged for the investigation, which is ongoing with no conclusions reached yet [2]. - Despite the investigation, the Company believes it will not materially affect its previously announced preliminary financial results for the fourth quarter and fiscal year ended March 31, 2025 [2]. Company Background - PetMed Express, Inc. was founded in 1996 and is a pioneer in the direct-to-consumer pet healthcare sector [3]. - The Company operates as a national online pharmacy licensed across all 50 states, offering a range of pet health solutions including pharmaceuticals and OTC supplements [3]. - PetMeds aims to empower pet owners to enhance the health and wellness of their pets [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2] - Following the announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against PetMed Express, Inc. for possible violations of federal securities laws and unlawful business practices [1]. Group 1: Company Announcement - On June 10, 2025, PetMed announced a delay in the release of its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2]. - Following this announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2]. Group 2: Legal Investigation - The law firm is reaching out to PetMed stockholders who may have suffered losses and are interested in learning more about potential claims [3]. - The firm emphasizes that there is no cost or obligation for stockholders to inquire about their rights or interests regarding these matters [3]. Group 3: Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California, representing individual and institutional investors in various types of litigation [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [3] - Following the announcement of the delay, PetMed's stock price dropped by $0.47 per share, representing an 11.22% decline, closing at $3.72 per share on June 11, 2025 [3] Group 2: Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of fighting for victims of securities fraud and corporate misconduct [4]